Published in Retina

Inside Mass Eye and Ear's Vitrectomy Course: A 16-Year Model for First-Year Fellow Training

This is editorially independent content
3 min read

Join Drs. Singh and Miller as they discuss the 16th annual Vitrectomy Course for first-year fellows and the model behind the program.

Founded by John I. Loewenstein, MD and Demetrios G. Vavvas, MD, PhD, the Mass Eye and Ear Vitrectomy Course marks its 16th year this July, continuing a curriculum built specifically for first-year retina fellows.
In this episode of Evidence Based Retina, Rishi Singh, MD, FASRS joins John Miller, MD—course director and associate professor of ophthalmology at Mass Eye and Ear—to discuss this unique educational experience.

It's a really special opportunity to see Mass Eye and Ear functioning in prime time with our own nurses and a really high faculty-to-fellow ratio of one-to-one or greater per trainee.

Vitrectomy course fast facts

Now, in its 16th year, the Vitrectomy Course at Mass Eye and Ear:1

  • Was designed specifically for first-year fellows in their earliest weeks of training.
  • Has a faculty-to-fellow ratio of one-to-one or greater per trainee.
  • Utilizes lectures, panels, video simulations, and hour-long wet labs to teach the theory and practice of vitreoretinal surgery.
  • Is scheduled for July 10 and 11, intentionally placed during fellows' first week, to provide invaluable training as they take the step up from residency and assume independent surgical responsibilities.

We hope that by inserting this course into that first week, it's really like a boot camp or an orientation.

A look at leadership

Dr. Miller leads a team of five course directors organizing the two-day program for roughly 100 participants. Along with Dr. Miller, this year's dedicated directors include returning faculty Elizabeth Rossin, MD, PhD; Nimesh Patel, MD along with first-time leaders Jose Davila, MD and K. Matthew McKay, MD. In addition, a group of eminent guest instructors will share their pearls and perspectives.

I think the faculty love coming to this course because of the fellow to faculty ratio.

Other key educators from across the country and even internationally will be joining the course, including Mario Romano MD, PhD a full Professor of Ophthalmology and Director of the Resident Program, Humanitas University, Milan, Italy; Sophie Bakri Professor and Chair of the Department of Ophthalmology at Mayo Clinic in Rochester, Minnesota; and Sharon Fekrat MD, FACS, FASRS of Duke Eye Center.

Core curriculum

With a focus on vitreoretinal surgery, the course combines didactics, video simulation, and hands-on wet labs held directly in the Mass Eye and Ear OR. By leveraging their surgical space on Saturday when the regular staff are not operating, the course provides full capacity operating in the same rooms where the doctors are repairing retinal detachments and performing other retinal surgeries throughout the week. Wet labs run for a full hour per station.
The course exposes fellows to vitrectomy machines from multiple vendors, including Alcon, B+L, and Dorc, along with microscopes from various manufacturers and 3D heads-up visualization and intraoperative OCT.

It's a great opportunity for fellows to see a wide range of technology and offers cutting-edge opportunities for visualization that may go beyond what they might even see during their fellowship. It might be the only chance they really get to see that type of equipment.

In closing

With five course directors, a faculty roster drawing from across the country and internationally, and a one-to-one or greater faculty-to-fellow ratio, the Vitrectomy Course continues to usher ophthalmology residents into fellowship with intensive instruction in the theory and practice of vitreoretinal surgery.
  1. Vitrectomy Course. Harvard Medical School Department of Ophthalmology. https://eye.hms.harvard.edu/vrcourse.
Rishi P. Singh, MD, FASRS
About Rishi P. Singh, MD, FASRS

Rishi P. Singh, MD, FASRS, is the Chair of the Department of Ophthalmology at Mass General Brigham, overseeing ophthalmology across Massachusetts Eye and Ear, Massachusetts General Hospital, Brigham and Women’s Hospital, and affiliated sites. He is also a Professor of Ophthalmology at Harvard Medical School.

Previously, Dr. Singh served as Vice President and Chief Medical Officer at Cleveland Clinic Martin Health in Stuart, Florida, and as a staff surgeon at the Cleveland Clinic, where he was also Professor of Ophthalmology at the Cleveland Clinic Lerner College of Medicine in Cleveland, Ohio. He received both his undergraduate degree in medical science and his medical degree from Boston University, completing his internship at Tufts University. Dr. Singh went on to complete his ophthalmology residency at the Massachusetts Eye and Ear Infirmary/Harvard Medical School and a medical and surgical vitreoretinal fellowship at the Cole Eye Institute at the Cleveland Clinic.

Dr. Singh specializes in the management of complex retinal diseases, including diabetic retinopathy, retinal vein occlusions, retinal detachment, and age-related macular degeneration. He has authored over 300 peer-reviewed publications, books, and book chapters and serves as Principal Investigator for numerous national and international clinical trials aimed at improving outcomes for patients with retinal diseases.

He is the founder and past president of the Retina World Congress, chairs some of the largest continuing medical education meetings in retina, and serves on editorial boards and review panels for major ophthalmology journals. His leadership has extended into digital innovation, having helped lead enterprise-wide implementation of clinical technologies including Epic modules, digital informed consent, and patient-facing kiosks.

Dr. Singh has received multiple accolades for his contributions to ophthalmic research and innovation, including the Alpha Omega Alpha Research Award, the American Society of Retina Specialists Young Investigator Award, and the J. Donald Gass Beacon of Sight Award. He also leads The Center for Ophthalmic Bioinformatics, a research initiative focused on leveraging big data and artificial intelligence to advance understanding and treatment of retinal disease.

Rishi P. Singh, MD, FASRS
John Miller, MD
About John Miller, MD

John B. Miller, MD is a retina specialist and associate professor of ophthalmology at Mass Eye and Ear. He is interested in macular degeneration, diabetic retinopathy, retinal detachment, retinal vascular occlusions, trauma, macular telangiectasia, and complex medical and surgical retinal problems. Surgically, he specializes in retinal detachment repair, including complex retinal detachments related to proliferative vitreoretinopathy or traumatic injuries, macular holes, epiretinal membranes (macular pucker), and dislocated lenses.

Dr. Miller maintains an active research program in addition to his strong clinical retina practice. As a clinician scientist, his work focuses both on clinical research and the basic mechanisms of retinal disease through study in the laboratory. In the Ines and Frederick Yeatts Retina Research Laboratory at Mass Eye and Ear, he has explored the mechanisms of retinal toxicity of systemic medications. Ongoing work explores the pathogenesis of age-related macular degeneration, macular telangiectasia, macular hole, and drug retinal toxicities.

His clinical research includes age-related macular degeneration, traumatic macular holes, macular telangiectasia. He has particularly focused on retinal imaging devices, including swept-source OCT (investigational). With additional advances in retinal imaging, he hopes to provide earlier detection of disease or predisposing factors, better prognostic information, and disease maintenance.

Additionally, he plays an important role training ophthalmology residents and retina fellows in the clinic and operating room as a Core Faculty Member of the Harvard Ophthalmology Residency program and the Associate Director of the Vitreoretinal Fellowship.

John Miller, MD
💙 Evidence Based Retina
Astellas
Regeneron
Bausch + Lomb Xipere
EyePoint Pharmaceuticals
Apellis Pharmaceuticals
Norlase